Welcome to the HealthSmart Pharmacy Immunisation Booking System

Phone: 03 9045 9777

* Fields marked with an asterisk must be completed
Time left to complete this booking: 15:00

About Your Vaccination

Your appointment will take approximately 2 minutes. You can access the HealthSmart Pharmacy Privacy statement here 

If you cannot attend your appointment, please reschedule it, or contact the pharmacy for a refund.

Payment is to hold your vaccine and booking - there are no refunds on cancellations except in select circumstances.

Recheduling holds your booking details and your payment.

Please note, there is a mandatory requirement for anyone who has received a vaccine to stay in the proximity of the vaccination service for 15 minutes after receiving the vaccination, so our Pharmacist Immuniser can effectively manage any adverse events following immunisation (AEFI).

During your appointment, the following will occur:
- The Pharmacist Immuniser will ask questions to ensure you are safe to have the vaccine
- In line with Australian Best Practice Standards, the Pharmacist Immuniser may not swab the skin or wear gloves before you receive your vaccination

Our Pharmacist Immuniser will administer the vaccine and provide you with a band aid or appropriate dressing.

Post vaccination wait time: 15 mins

This is a private vaccination and will require payment ($350) at time of vaccination

 

A single dose of Abrysvo is recommended for pregnant women at 28–36 weeks gestation to protect the infant.

Abrysvo is the only RSV vaccine approved for use in pregnant women. Arexvy should not be given to pregnant women.

See Table. Vaccines that are routinely recommended in pregnancy: inactivated vaccines in Vaccination for women who are planning pregnancy, pregnant or breastfeeding for more details.

RSV infection in infants often causes lower respiratory tract disease, such as bronchiolitis. It is most likely to be severe during the first 6 months of life, frequently requiring hospitalisation. Maternal immunisation reduces the risk of severe RSV disease in infants <6 months of age by around 70% (see Vaccine information). This is the result of passive protection by transplacental transfer of RSV-specific antibodies from the mother to the fetus during pregnancy.

Maternal RSV vaccine is administered mainly to protect newborn infants. Vaccination may also protect pregnant women against RSV disease, but this is usually mild in women of child-bearing age and clinical trials did not study protection to the mother from vaccination.

Advice on potential repeat vaccination during subsequent pregnancies will be provided in the future as more data become available. The need for vaccination during each pregnancy is anticipated based on immunologic principles and experience with other vaccines recommended in pregnancy.

Women who are breastfeeding but not pregnant are not recommended to receive an RSV vaccine. There are no theoretical safety concerns, but there is also no evidence that vaccination would protect the infant through breastfeeding alone.

Timing of vaccination during pregnancy

Timing of vaccination during pregnancy

The recommended time for RSV vaccination during pregnancy is between 28 and 36 weeks gestation. Although Abrysvo is registered from 24 to 36 weeks gestation, administration from 24 to <28 weeks of gestation is not routinely recommended until there are more safety and efficacy data for women vaccinated at this gestation and their newborn infants.

RSV vaccine can be given at any time of the year, regardless of when a pregnant woman is expected to deliver.

If a pregnant woman is not vaccinated before 36 weeks gestation, they should receive the vaccine as soon as possible after 36 weeks gestation. An immune response to the vaccine develops within the weeks after vaccination and transplacental antibody transfer to the infant increases progressively from the time of vaccination. However, infants are not expected to be adequately protected unless they are born at least 2 weeks after the mother received the vaccine.1

If delivery occurs within 2 weeks of the mother receiving the RSV vaccine, the infant is recommended to receive nirsevimab (a long-acting RSV-specific monoclonal antibody) to provide additional protection.

If a pregnant woman inadvertently receives RSV vaccine earlier than 28 weeks gestation, a repeat dose during the same pregnancy is not recommended.

The recommended timing of vaccination during pregnancy considers that:

  • further safety data on vaccination at an earlier gestational age than 28 weeks will be reviewed as these data become available (see Precautions – women who are pregnant or breastfeeding)
  • RSV is a seasonal disease in most parts of Australia, but severe disease can occur outside of peak seasons as RSV circulation continues year-round. Seasonality differs by jurisdiction in Australia, particularly in the tropical regions
  • RSV vaccines can be given at the same time as, or separate to, dTpa, influenza and COVID-19 vaccines (see Co-administration with other vaccines).

A single dose of Arexvy RSV vaccine is recommended for the following groups:

• All adults aged ≥75 years, who have the highest burden of RSV hospitalisation and are likely to have the greatest benefit from vaccination.

• Aboriginal and/or Torres Strait Islander peoples aged 60 to 74 years, who have a rate of RSVassociated hospitalisation that is similar to non-Indigenous Australians aged ≥75 years.

• Adults aged 60 to 74 years with medical conditions that increase their risk of severe disease due to RSV 

 

All other adults aged 60 to 74 years can consider RSV vaccination. The burden of RSV disease is lower in this age group than in people aged ≥75 years, so the benefits of vaccination may be less.  

This is a privately funded vaccine. You will be required to pay before administration. Cost is $350

https://www.health.gov.au/sites/default/files/2024-02/atagi-statement-on-the-clinical-use-of-arexvy-rsv-pre-f3-vaccine-for-rsv.pdf

Stay protected in 2024: Your guide to COVID-19 vaccination
Ensure your ongoing protection against COVID-19 by understanding the latest vaccination guidelines for 2024. 
As with all vaccinations, people are encouraged to discuss the vaccine options available to them with their health practitioner. You can also use the booster eligibility tool to determine whether you are eligible for a COVID-19 booster vaccination.
75 years and older
  • Recommended every 6 months.
65-74 years
  • Recommended at least every 12 months, but can receive every six months. Talk to your healthcare provider about the risks and benefits..
18-64 years
  • With severe immunocompromise: Recommended at least every 12 months, but can receive every six months. Talk to your healthcare provider about the risks and benefits. 
  • Without severe immunocompromise: Can receive every 12 months.
5-17 years
  • With severe immunocompromise: Can receive every 12 months.
  • Without severe immunocompromise: Not recommended.
Under 5 years
 
  • Not recommended.

The influenza vaccines are free under the National Immunisation Program for:

  • Aboriginal and Torres Strait Islander people aged 6 months and over
  • Children aged 6 months to under 5 years
  • Pregnant women at any stage of pregnancy
  • People aged 65 years or over
  • People aged 6 months or over who have medical conditions that mean they have a higher risk of getting serious disease:
    • cardiac disease
    • chronic respiratory conditions
    • immunocompromising conditions
    • haematological disorders
    • chronic metabolic disorder
    • chronic kidney disease
    • chronic neurological condition
    • long term aspirin therapy in children aged 5 to 10 years.

 

Click here for more information

The influenza vaccines are free under the National Immunisation Program for:

  • Aboriginal and Torres Strait Islander people aged 6 months and over
  • Children aged 6 months to under 5 years
  • Pregnant women at any stage of pregnancy
  • People aged 65 years or over
  • People aged 6 months or over who have medical conditions that mean they have a higher risk of getting serious disease:
    • cardiac disease
    • chronic respiratory conditions
    • immunocompromising conditions
    • haematological disorders
    • chronic metabolic disorder
    • chronic kidney disease
    • chronic neurological condition
    • long term aspirin therapy in children aged 5 to 10 years.

 

Click here for more information

THIS VACCINE REQUIRES A BOOSTER 28 DAYS POST FIRST DOSE

FOR AFTERHOURS BOOKINGS (AFTER 4PM) PLEASE CALL THE PHARMACY TO ENSURE THAT THE VACCINATOR IS QUALIFIED TO ADMINISTER THIS VACCINE

Please check current eligibility criteria by following this link before making your booking. 

Current Eligibility Criteria

Mpox (formerly monkeypox) is a disease caused by infection with the monkeypox virus and is an urgent notifiable condition in Victoria.

Since May 2022, there has been a multi-country outbreak of mpox which has mostly impacted gay, bisexual and other men who have sex with men.

In Victoria, the risk of local transmission and transmission linked to international travel remains.

Mpox can be spread from person-to-person through skin-to-skin contact, contaminated surfaces, and respiratory droplets.

Symptoms include rash, fever, chills, tiredness, headache, sore throat, muscle aches and swollen lymph nodes. Proctitis or urethritis can also occur.

Vaccination can protect against infection and severe disease. Free mpox vaccine is widely available for eligible people through sexual health clinics, public hospitals, general practitioners, Aboriginal health services, pharmacies and some local councils


We charge an adminstration fee to deliver this vaccine

 

https://www.health.vic.gov.au/infectious-diseases/mpox-monkeypox#eligibility-criteria

Who should get vaccinated against shingles

Free shingles vaccination under the National Immunisation Program (NIP) is available for eligible people most at risk of complications from shingles.

A 2-dose course of Shingrix is available for free for:

  • people aged 65 years and over
  • First Nations people aged 50 years and over
  • immunocompromised people aged 18 years and over with the following medical conditions:
    • haematopoietic stem cell transplant
    • solid organ transplant
    • haematological malignancy
    • advanced or untreated HIV.

If you previously received a free Zostavax shingles vaccine under the NIP, you are not eligible for a free Shingrix vaccine for at least 5 years.  

If you purchased the Zostavax vaccine privately, you can receive Shingrix for free under the program if you’re eligible.

You should wait at least 12 months between receiving Zostavax and getting the Shingrix vaccine. 

Talk to your health professional about your eligibility for the free shingles vaccine today.  

 

https://www.health.gov.au/topics/immunisation/vaccines/shingles-herpes-zoster-immunisation-service

Free shingles vaccination under the National Immunisation Program (NIP) is available for eligible people most at risk of complications from shingles.

A 2-dose course of Shingrix is available for free for:

  • people aged 65 years and over
  • First Nations people aged 50 years and over
  • immunocompromised people aged 18 years and over with the following medical conditions:
    • haematopoietic stem cell transplant
    • solid organ transplant
    • haematological malignancy
    • advanced or untreated HIV.

If you previously received a free Zostavax shingles vaccine under the NIP, you are not eligible for a free Shingrix vaccine for at least 5 years.  

If you purchased the Zostavax vaccine privately, you can receive Shingrix for free under the program if you’re eligible.

You should wait at least 12 months between receiving Zostavax and getting the Shingrix vaccine. 

Talk to your health professional about your eligibility for the free shingles vaccine today.  

 

https://www.health.gov.au/topics/immunisation/vaccines/shingles-herpes-zoster-immunisation-service

Personal Details

General Consents

Terms & Conditions

These terms apply to the administration to you of the Vaccination from an Pharmacist Immuniser for HealthSmart. By consenting to receive the Vaccination, you confirm that you have read and agreed to the following terms: 
 

 I confirm and agree the following:          

  1. I am the minimum required age for administering this vaccine.
  2. I understand that the vaccine is subject to availability.   
  3. I have read the Consumer Medicine Information (CMI) sheet for this vaccination 
  4. I have read and understand information on precautions, contraindications and side effects (listed in each CMI and below), am aware of and accept any risks associated with the Vaccination and to my knowledge I do not suffer from any condition or circumstance that prevents me from having the Vaccination or makes it unsafe for me.
  5. I will answer truthfully if the Pharmacist Immuniser asks for specific information about my health, past vaccinations or other conditions that may affect my participation.   
  6. I will immediately inform the Pharmacist Immuniser of any adverse changes I experience in the course of participating in the Vaccination or afterwards, including (but not limited to): discomfort, pain, dizziness, shortness of breath, wheezing, difficulty breathing, swelling of the face, lips, tongue or other parts of the body.  
  7. I understand that as part of receiving the Vaccination, HealthSmart Pharmacy must securely submit a record of my Vaccination to the Australian Immunisation Register (AIR).   
  8. HealthSmart Pharmacy and its employees, agents, sub-contractors, directors and related bodies corporate will not be responsible for any injury, loss or damage you suffer from the Vaccination (except where liability cannot be excluded by law).                  

Precautions and Contraindications

I agree to let the Pharmacist Immuniser know prior to the Vaccination if I:

  • have had an allergic reaction to any previous vaccine   
  • have recently had any other vaccine (e.g. COVID-19 vaccine)   
  • are allergic to the active ingredients or any other ingredients in the vaccines  
  • are suffering from an acute illness (e.g. an infection) or have a temperature higher than 38.5ºC  
  • have or have had an immune response or low immunity problem e.g. a disorder, corticosteroid, cyclosporin or cancer treatment (including radiation therapy)  
  • have or had allergies or allergic reactions e.g. itchy rash/hives, swelling of face, lips, mouth or tongue  
  • have a bleeding problem or bruise easily  
  • have ever fainted before, during or after having an injection  
  • have a known allergy to egg protein  
  • have a known allergy to latex, foods, preservatives or dyes  
  • intend to become pregnant, are pregnant or breast-feeding   
  • have or have had Guillain - Barre Syndrome (an illness which affects the nervous system and can cause severe muscle weakness or paralysis) after getting a flu vaccine. 

         
 I understand that having one of these issues may not prevent me from having the vaccine, but having a discussion with the Pharmacist Immuniser beforehand will allow me to make an informed choice about vaccination. 

 

Side effects   

I understand that, like all medicines, these vaccines may have some mild side effects, such as pain, tenderness, redness, swelling, bruising and hardness at the injection site, flu-like symptoms such as headaches, muscles aches, sore throat, cough, fever and chills/shivering or other symptoms like nausea, vomiting or diarrhoea.  

I understand that these symptoms do not mean I am sick, they are most likely to be my body’s natural response to the vaccine. The vaccine cannot give me an illness as it does not contain any live virus. The vaccine is generally well tolerated however I should stay close by so that the nurse can keep an eye on me for 15 minutes after the vaccine. 
                

Australian Immunisation Register (AIR) Reporting 
                
The Australian Government has introduced laws to ensure that every Australian can access their vaccine history through a safe and secure register. Vaccination providers must now report information in relation to vaccinations administered both within and outside Australia. To facilitate this reporting we may need to collect some additional personal information from you such as your Medicare details (if applicable) in order to submit a record of your Vaccination to the AIR.  
                

 
Please answer all the questions ( scroll up you might have missed some questions ).

Eligibility Questionnaire